The "biggest wave" is coming, with new crown vaccines or increased SUDs for HIV

: Vaccines are considered the most powerful way to address pandemics, but warnings are emerging.
The new crown outbreak is still in the global pandemic, with the arrival of autumn and winter in Europe, the United States, a fierce counter-attack. In particular, the outbreak in Europe is "extremely serious", has become the "epicenter", 9 days on the new million new crown cases, countries are taking more stringent measures, including curfews, in order to pull the tide, and the United States new crown outbreak of the "biggest wave" is coming.At the same time, the international leading new crown vaccine competition has entered the white heat phase, according to the latest data released by WHO, as of 19 October, the world has developed 198 candidate new crown vaccine, 44 of which are being tested in humans. Countries are counting on effective vaccines to be introduced as soon as possible to effectively control the outbreak in order to alleviate the current predicament.On October 19th, WHO Director-General Tan Desser said at a briefing on the new crown that 184 countries and economies around the world had joined the New Crown Pneumonia Vaccine Implementation Programme, with Ecuador and Uruguay the latest to join.“ The New Crown Pneumonia Vaccine Implementation Plan "is considered to be the most effective mechanism for equitable sharing of safe and effective vaccines worldwide and is of great positive significance for maintaining the stability of the global health system and truly promoting global economic recovery." On October 8, China signed an agreement with the Global Alliance for Vaccine Immunization to formally join the New Coronary Pneumonia Vaccine Implementation Program.In China, 13 vaccine candidates have entered clinical trials, four of which were in Phase III clinical trials, and 60,000 volunteers received the four vaccine candidates without significant adverse reactions. But since the outbreak in China is under control, it is difficult to conduct such tests at home.There is a global interest in the race for new crown vaccines, and leading new crown candidates have passed laboratory trials and multiple phases of clinical trials at a record rate, showing that they produce good immune response and safety, but many questions remain to be answered.Some candidates for the new crown vaccine may increase susceptible to HIV, senior researchers have warned recently. In an online newsletter published in The Lancet, four researchers involved in a placebo-controlled AIDS vaccine trial called STEP warned candidates for the new coronary vaccine.They write that an assessment of step and Phambili Phase 2b studies completed more than a decade ago found an increased risk of HIV-1 infection from the use of the Ad5 vector HIV-1 vaccine in three immunizations, and a similar increased risk of HIV infection was observed in heterosexual men who participated in the Phambili study. Step tests found that men who tested positive for Ad5 serum and did not under foreskinding had a higher risk of HIV-1 infection in the first 18 months of follow-up. This time node issues a "warning" that it is important to consider the potential use of the Ad5 vector in new coronavirus infections and that these vaccine-candidate trials may soon begin in areas where HIV epidemics have been declared.In fact, as early as late September 2007, Merck developed a highly-expected Ad5 vector HIV vaccine that could increase the risk of HIV infection in inoculators and end hiv levels in people with HIV by failing to prevent infection and reduce blood levels in people living with AIDS.Previously, the researchers stressed that the AIDS vaccine itself does not cause AIDS, but the type 5 adenovirus may activate the body's immune system in a unique way, making certain people exposed to HIV susceptible. The Lancet editorial sets out several possibilities, including reducing HIV immunity, enhancing the replication of the AIDS virus, or setting more target cells for it.Dr. Anthony Fauci, a top U.S. infectious disease expert and senior AIDS researcher at the U.S. National Institute of Allergy and Infectious Diseases, said in a previous paper that the side effects are likely to be unique to the HIV vaccine. But they caution that hiv rates should be monitored during and after trials of all Ad5-based vaccines in high-risk populations."I'm concerned about using these vaccines in any population or country at risk of HIV, including in the United States," said Dr. Larry Corey, co-director of the U.S. Coronavirus Vaccine Prevention Network.Ad5 also acts as a "carrier" in candidate new crown vaccines that are currently being tested in clinical trials in several countries, including China, the United States and Russia. These include the vaccine developed jointly by the Institute of Bioengineering of the Institute of Military Medicine of the Chinese Academy of Military Sciences and Concino Bios, a modified form of adenovirus vector 5 or Ad5; Two of them have been conducted in Large-scale Phase III clinical trials in Russia and Pakistan.It should be noted, however, that there is no evidence that any of these adenovirus vaccines increase the risk of HIV infection. However, in the context of pandemics, surveillance of the incidence of such vaccines and AIDS needs to be strengthened. (MedScimes)